New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 13, 2014
07:37 EDTENTAEnanta Pharmaceuticals reports Q1 EPS (30c), consensus (15c)
Reports Q1 revenue $893K, consensus $1.41M. The company said, "The changes in revenue for the three-month periods are primarily related to the timing and amount of milestone and other payments from collaborations, which have varied significantly from period to period and are expected to continue to do so."
News For ENTA From The Last 14 Days
Check below for free stories on ENTA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 18, 2014
07:51 EDTENTAAlan Dworsky reports 5.4% passive stake in Enanta
Subscribe for More Information
September 10, 2014
10:24 EDTENTAEnanta announces AbbVie initiated Phase 2b trial with ABT-493
Enanta (ENTA) announced that AbbVie (ABBV) initiated a phase 2b clinical study with ABT-493, Enanta’s next-generation protease inhibitor. ABT-493 is the second clinical-stage protease inhibitor candidate developed within the Enanta-AbbVie collaboration. The phase 2b study being conducted by AbbVie will evaluate the safety and efficacy of ABT-493 co-administered with ABT-530 in HCV patients. AbbVie has informed Enanta that results from this trial are expected in 2015 and AbbVie plans to start phase 3 development of the combination next year.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use